Updates are available Correction dated 2023-06-23
Click to view Correction: https://doi.org/10.1038/s41467-023-39001-7
-
Authors
Paul, Kimberly C. https://orcid.org/0000-0002-4476-2352
Krolewski, Richard C. https://orcid.org/0000-0001-5974-079X
Lucumi Moreno, Edinson
Blank, Jack https://orcid.org/0000-0003-1674-0444
Holton, Kristina M.
Ahfeldt, Tim
Furlong, Melissa
Yu, Yu https://orcid.org/0000-0001-8717-0245
Cockburn, Myles
Thompson, Laura K. https://orcid.org/0000-0001-9581-9032
Kreymerman, Alexander
Ricci-Blair, Elisabeth M.
Li, Yu Jun
Patel, Heer B.
Lee, Richard T. https://orcid.org/0000-0003-4687-1381
Bronstein, Jeff
Rubin, Lee L. https://orcid.org/0000-0002-8658-841X
Khurana, Vikram https://orcid.org/0000-0002-4018-5527
Ritz, Beate https://orcid.org/0000-0001-6976-7339
- License Information
-
More Information
Article History
Received: 21 June 2022
Accepted: 20 April 2023
First Online: 16 May 2023
Change Date: 23 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-39001-7
Competing interests
: L.L.R. is a founder of and a member of the Scientific Advisory Board of Vesalius Therapeutics, a private biotechnology company, and an owner of stock options. He is a member of the Scientific Advisory Board of Yumanity Therapeutics and a shareholder. Both companies study Parkinson’s disease. B.R., M.C., and R.C.K. have been retained as expert consultants for plaintiffs in a lawsuit on the role of paraquat in Parkinson’s disease causation. V.K. is a co-founder of and senior advisor to DaCapo Brainscience and Yumanity Therapeutics, companies focused on central nervous system diseases. The remaining authors declare no competing interests.
